联环药业：公司原料药产品左炔诺孕酮通过世界卫生组织预认证

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel, has passed the WHO prequalification process [1] Group 1: WHO Prequalification - The product Levonorgestrel has successfully undergone on-site inspection and the Drug Master File (DMF) review by the WHO, achieving full prequalification [1] - This prequalification is expected to enhance the company's credibility in the global market [1] Group 2: Financial Impact - The prequalification is not anticipated to have a significant impact on the company's current operating performance [1] - Future sales orders for the product remain uncertain, indicating potential variability in revenue generation [1]